NCT Number: NCT05633160
Phase: PHASE1|PHASE2
Trial Summary: The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer i – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Clarity Pharmaceuticals Ltd
Acronym: COMBAT
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives